NO20064412L - Kondensert heterocykelderivat, medisinsk sammensetning inneholdende det samme og medisinsk anvendelse derav - Google Patents
Kondensert heterocykelderivat, medisinsk sammensetning inneholdende det samme og medisinsk anvendelse deravInfo
- Publication number
- NO20064412L NO20064412L NO20064412A NO20064412A NO20064412L NO 20064412 L NO20064412 L NO 20064412L NO 20064412 A NO20064412 A NO 20064412A NO 20064412 A NO20064412 A NO 20064412A NO 20064412 L NO20064412 L NO 20064412L
- Authority
- NO
- Norway
- Prior art keywords
- following general
- general formula
- same
- medical
- group
- Prior art date
Links
- 125000000623 heterocyclic group Chemical group 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 201000001421 hyperglycemia Diseases 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 208000002249 Diabetes Complications Diseases 0.000 abstract 1
- 208000002705 Glucose Intolerance Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 102000000070 Sodium-Glucose Transport Proteins Human genes 0.000 abstract 1
- 108010080361 Sodium-Glucose Transport Proteins Proteins 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000009104 prediabetes syndrome Diseases 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Den foreliggende oppfinnelse tilveiebringer nitrogeninneholdende kondenserte cycliske derivater representert ved den følgende generelle formel eller farmasøytisk akseptable salter derav, eller prodroger derav. De har human SGLT-inhiberende aktivitet og er nyttige som et forebyggende eller terapeutisk middel for sykdommer forbundet med hyperglykemi slik som diabetes, postprandial hyperglykemi, nedsatt glukosetoleranse, diabeteskomplikasjoner og obesitet. I formel (I)representerer én av R1 og R4 en gruppe representert ved den følgende generelle formel (S) (hvori R og R representerer H, OH, et halogen, osv.; Q representerer en alkylengruppe osv.; og ring A representerer en arylgruppe 2 osv.), og den andre representerer H, OH, en amino, osv.; R og R representerer hver H, OH, amino, halogen, og eventuelt 1 2 substituert alkyl, osv.; A representerer 0, S, osv.; A representerer CH eller N; G representerer en gruppe representert ved den følgende generelle formel (G-l) eller 1 2 (G-2) (E representerer H, F eller OH; og E representerer H, F, en metylgruppe, osv.), og farmasøytiske sammensetninger omfattende det samme, og farmasøytiske anvendelser derav.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004061429 | 2004-03-04 | ||
| PCT/JP2005/004152 WO2005085265A1 (ja) | 2004-03-04 | 2005-03-03 | 縮合ヘテロ環誘導体、それを含有する医薬組成物およびその医薬用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20064412L true NO20064412L (no) | 2006-12-04 |
Family
ID=34918063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20064412A NO20064412L (no) | 2004-03-04 | 2006-09-29 | Kondensert heterocykelderivat, medisinsk sammensetning inneholdende det samme og medisinsk anvendelse derav |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7732596B2 (no) |
| EP (1) | EP1724277A4 (no) |
| JP (1) | JP5078350B2 (no) |
| KR (1) | KR101214433B1 (no) |
| CN (1) | CN1934122B (no) |
| AU (1) | AU2005219777B2 (no) |
| CA (1) | CA2557320C (no) |
| IL (1) | IL177513A (no) |
| MA (1) | MA28512B1 (no) |
| NO (1) | NO20064412L (no) |
| NZ (1) | NZ549219A (no) |
| PL (1) | PL381247A1 (no) |
| RU (1) | RU2387663C2 (no) |
| TW (1) | TW200540167A (no) |
| WO (1) | WO2005085265A1 (no) |
| ZA (1) | ZA200606792B (no) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103467423B (zh) | 2004-03-16 | 2016-03-16 | 贝林格尔.英格海姆国际有限公司 | 吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法 |
| EP1828216B1 (en) | 2004-12-16 | 2008-09-10 | Boehringer Ingelheim International GmbH | Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
| TW200637869A (en) | 2005-01-28 | 2006-11-01 | Chugai Pharmaceutical Co Ltd | The spiroketal derivatives and the use as therapeutical agent for diabetes of the same |
| WO2006089872A1 (en) | 2005-02-23 | 2006-08-31 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted ( (hetero)arylethynyl-benzyd-benzene derivatives and use thereof as sodium-dependent glucose cotransporter 2 (sglt2) inhibitors |
| EP1874787B1 (en) | 2005-04-15 | 2009-12-30 | Boehringer Ingelheim International GmbH | Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives as sglt inhibitors |
| US7723309B2 (en) | 2005-05-03 | 2010-05-25 | Boehringer Ingelheim International Gmbh | Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
| UA91546C2 (uk) | 2005-05-03 | 2010-08-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ |
| US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
| WO2007014894A2 (en) | 2005-07-27 | 2007-02-08 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted ( (hetero) cycloalyklethynyl-benzyl) -benzene derivatives and use thereof as sodium-dependent glucose cotransporter (sglt) inhibitors |
| JP5175191B2 (ja) | 2005-08-30 | 2013-04-03 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グリコピラノシル置換ベンジルベンゼン誘導体、該化合物を含有する医薬品及びその使用と製造方法 |
| WO2007028814A1 (en) | 2005-09-08 | 2007-03-15 | Boehringer Ingelheim International Gmbh | CRYSTALLINE FORMS OF 1-CHLORO-4-(ß-D-GLUCOPYRANOS-1-YL)-2-(4-ETHYNYL-BENZYL)-BENZENE, METHODS FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS |
| AR056195A1 (es) | 2005-09-15 | 2007-09-26 | Boehringer Ingelheim Int | Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos |
| ATE517099T1 (de) | 2006-02-15 | 2011-08-15 | Boehringer Ingelheim Int | Glucopyranosyl-substituierte benzonitril-derivate,pharmazeutische zusammensetzungen mit derartigen verbindungen, ihre verwendung und herstellungsverfahren dafür |
| PE20080697A1 (es) | 2006-05-03 | 2008-08-05 | Boehringer Ingelheim Int | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| TWI432446B (zh) | 2006-07-27 | 2014-04-01 | Chugai Pharmaceutical Co Ltd | 稠環螺酮縮醇衍生物、及其做為糖尿病治療藥之使用 |
| TWI403516B (zh) | 2006-07-27 | 2013-08-01 | Chugai Pharmaceutical Co Ltd | To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes |
| TWI499414B (zh) | 2006-09-29 | 2015-09-11 | Lexicon Pharmaceuticals Inc | 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法 |
| MX2009003927A (es) * | 2006-10-13 | 2009-04-23 | Chugai Pharmaceutical Co Ltd | Derivado espirocetal de tioglucosa y uso del mismo como un agente terapeutico para la diabetes. |
| CN100586932C (zh) * | 2007-01-26 | 2010-02-03 | 中国医学科学院医药生物技术研究所 | 抗肿瘤化合物及其制备方法 |
| WO2008109591A1 (en) * | 2007-03-08 | 2008-09-12 | Lexicon Pharmaceuticals, Inc. | Phlorizin analogs as inhibitors of sodium glucose co-transporter 2 |
| CL2008002427A1 (es) | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2. |
| CL2008003653A1 (es) | 2008-01-17 | 2010-03-05 | Mitsubishi Tanabe Pharma Corp | Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica. |
| WO2010023594A1 (en) * | 2008-08-28 | 2010-03-04 | Pfizer Inc. | Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives |
| SG173619A1 (en) | 2009-02-13 | 2011-09-29 | Boehringer Ingelheim Int | Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof |
| WO2011039108A2 (en) | 2009-09-30 | 2011-04-07 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives |
| EA020798B1 (ru) | 2009-09-30 | 2015-01-30 | Бёрингер Ингельхайм Интернациональ Гмбх | СПОСОБ ПОЛУЧЕНИЯ КРИСТАЛЛИЧЕСКОЙ ФОРМЫ 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГИДРОФУРАН-3-ИЛОКСИ)БЕНЗИЛ]БЕНЗОЛА |
| US10610489B2 (en) | 2009-10-02 | 2020-04-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
| BR112012008924A2 (pt) | 2009-10-20 | 2019-09-24 | Novartis Ag | derivado de glicosídeo e usos do mesmo |
| US8163704B2 (en) | 2009-10-20 | 2012-04-24 | Novartis Ag | Glycoside derivatives and uses thereof |
| EA021983B1 (ru) | 2009-11-02 | 2015-10-30 | Пфайзер Инк. | Производные диоксабицикло[3.2.1]октан-2,3,4-триола |
| WO2011070592A2 (en) | 2009-12-09 | 2011-06-16 | Panacea Biotec Ltd. | Novel sugar derivatives |
| UY33937A (es) | 2011-03-07 | 2012-09-28 | Boehringer Ingelheim Int | Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina |
| US8614195B2 (en) | 2011-04-14 | 2013-12-24 | Novartis Ag | Glycoside derivatives and uses thereof |
| WO2012140596A1 (en) | 2011-04-14 | 2012-10-18 | Novartis Ag | Glycoside derivatives and uses thereof |
| EP2755722B1 (en) | 2011-09-13 | 2017-05-24 | Panacea Biotec Ltd. | Novel sglt inhibitors |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| US9192617B2 (en) | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| HK1213818A1 (zh) | 2013-04-05 | 2016-07-15 | 勃林格殷格翰国际有限公司 | 依帕列净的治疗用途 |
| CA2812519A1 (en) | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| PT2981271T (pt) | 2013-04-05 | 2019-02-19 | Boehringer Ingelheim Int | Utilizações terapêuticas de empagliflozina |
| US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| SI2986304T1 (sl) | 2013-04-18 | 2022-04-29 | Boehringer Ingelheim International Gmbh | Farmacevtski sestavek, postopki za zdravljenje in njegove uporabe |
| CN104447893B (zh) * | 2013-09-25 | 2018-01-23 | 广东东阳光药业有限公司 | 吡喃葡萄糖基衍生物及其在医药上的应用 |
| CN109922813A (zh) | 2016-11-10 | 2019-06-21 | 勃林格殷格翰国际有限公司 | 药物组合物、治疗方法及其用途 |
| PL3716979T3 (pl) | 2017-11-30 | 2025-08-04 | Idorsia Pharmaceuticals Ltd | Połączenie pochodnej 4-pirymidynosulfamidu z inhibitorem sglt-2 do leczenia chorób związanych w endoteliną |
| CN116283895A (zh) * | 2023-01-09 | 2023-06-23 | 怀化宝华生物科技有限公司 | 一种2-[2-(噻吩基)乙基]苯甲酸的制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5582837A (en) * | 1992-03-25 | 1996-12-10 | Depomed, Inc. | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
| HUT70954A (en) * | 1992-04-03 | 1995-11-28 | Upjohn Co | Bicyclic-heterocyclic amines containing nitrogen heteroatoms |
| US5502187A (en) | 1992-04-03 | 1996-03-26 | The Upjohn Company | Pharmaceutically active bicyclic-heterocyclic amines |
| US6515117B2 (en) * | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| PH12000002657B1 (en) * | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
| ES2218338T3 (es) | 2000-04-13 | 2004-11-16 | Pfizer Products Inc. | Efecto sinergico de gliburida y milrinona. |
| JP2002193948A (ja) | 2000-10-06 | 2002-07-10 | Sankyo Co Ltd | α−置換カルボン酸誘導体を含有する糖尿病治療剤 |
| KR100882179B1 (ko) | 2001-06-20 | 2009-02-06 | 깃세이 야쿠힌 고교 가부시키가이샤 | 함질소 복소환 유도체, 그것을 함유하는 의약 조성물, 그의약 용도 및 그 제조 중간체 |
| JP4115105B2 (ja) * | 2001-07-02 | 2008-07-09 | 協和醗酵工業株式会社 | ピラゾール誘導体 |
| EP1495019B1 (en) * | 2002-04-08 | 2008-07-02 | Council of Scientific and Industrial Research | Glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof |
| TWI254635B (en) * | 2002-08-05 | 2006-05-11 | Yamanouchi Pharma Co Ltd | Azulene derivative and salt thereof |
| JP4222450B2 (ja) * | 2003-03-14 | 2009-02-12 | アステラス製薬株式会社 | Ｃ−グリコシド誘導体又はその塩 |
| JP2004300102A (ja) | 2003-03-31 | 2004-10-28 | Kissei Pharmaceut Co Ltd | 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途 |
| AU2005219779B2 (en) * | 2004-03-04 | 2011-04-14 | Kissei Pharmaceutical Co., Ltd. | Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof |
-
2005
- 2005-03-03 PL PL381247A patent/PL381247A1/pl not_active Application Discontinuation
- 2005-03-03 NZ NZ549219A patent/NZ549219A/en not_active IP Right Cessation
- 2005-03-03 ZA ZA200606792A patent/ZA200606792B/xx unknown
- 2005-03-03 RU RU2006131552/04A patent/RU2387663C2/ru not_active IP Right Cessation
- 2005-03-03 JP JP2006510804A patent/JP5078350B2/ja not_active Expired - Fee Related
- 2005-03-03 WO PCT/JP2005/004152 patent/WO2005085265A1/ja not_active Ceased
- 2005-03-03 US US10/591,403 patent/US7732596B2/en not_active Expired - Fee Related
- 2005-03-03 CN CN2005800062115A patent/CN1934122B/zh not_active Expired - Fee Related
- 2005-03-03 CA CA2557320A patent/CA2557320C/en not_active Expired - Fee Related
- 2005-03-03 AU AU2005219777A patent/AU2005219777B2/en not_active Ceased
- 2005-03-03 EP EP05720423A patent/EP1724277A4/en not_active Withdrawn
- 2005-03-04 TW TW094106585A patent/TW200540167A/zh not_active IP Right Cessation
-
2006
- 2006-08-16 IL IL177513A patent/IL177513A/en not_active IP Right Cessation
- 2006-09-20 KR KR1020067019362A patent/KR101214433B1/ko not_active Expired - Fee Related
- 2006-09-29 NO NO20064412A patent/NO20064412L/no not_active Application Discontinuation
- 2006-10-02 MA MA29361A patent/MA28512B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2557320A1 (en) | 2005-09-15 |
| NZ549219A (en) | 2010-08-27 |
| IL177513A0 (en) | 2006-12-10 |
| IL177513A (en) | 2011-11-30 |
| RU2006131552A (ru) | 2008-03-10 |
| US20070197449A1 (en) | 2007-08-23 |
| JP5078350B2 (ja) | 2012-11-21 |
| KR20060132737A (ko) | 2006-12-21 |
| EP1724277A1 (en) | 2006-11-22 |
| CN1934122B (zh) | 2010-08-04 |
| AU2005219777B2 (en) | 2011-02-03 |
| US7732596B2 (en) | 2010-06-08 |
| HK1099556A1 (zh) | 2007-08-17 |
| AU2005219777A1 (en) | 2005-09-15 |
| ZA200606792B (en) | 2007-12-27 |
| CA2557320C (en) | 2013-02-05 |
| KR101214433B1 (ko) | 2012-12-21 |
| WO2005085265A1 (ja) | 2005-09-15 |
| JPWO2005085265A1 (ja) | 2008-01-17 |
| CN1934122A (zh) | 2007-03-21 |
| MA28512B1 (fr) | 2007-04-03 |
| EP1724277A4 (en) | 2012-05-02 |
| TW200540167A (en) | 2005-12-16 |
| RU2387663C2 (ru) | 2010-04-27 |
| PL381247A1 (pl) | 2007-05-14 |
| TWI361190B (no) | 2012-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20064412L (no) | Kondensert heterocykelderivat, medisinsk sammensetning inneholdende det samme og medisinsk anvendelse derav | |
| ATE557030T1 (de) | Kondensiertes heterocyclisches derivat, dieses enthaltende medizinische zusammensetzung und deren medizinische verwendung | |
| NO20074012L (no) | 1-tio-D-glucitolderivater | |
| NO20082445L (no) | Neuropeptid-2 reseptor-agonister | |
| NO20020968D0 (no) | Glukopyranosyloksypyrazolderivater, medisinske sammensetninger inneholdende det samme og intermediater forfremstillingen derav | |
| ATE469161T1 (de) | Pyrazolderivat, dieses enthaltende medizinische zusammensetzung, medizinische verwendung davon, und zwischenprodukt für dessen herstellung | |
| NO20055680L (no) | Heksahydropyridoisokinoliner som DPP-IV-inhibitorer | |
| DE60208630D1 (de) | Thiazolderivate und ihre Verwendung als cdk-Inhibitoren | |
| NO20074872L (no) | Pyrazoler | |
| TW200606129A (en) | Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same | |
| NO20080789L (no) | 1,4-benzotiazepin 1,1-dioksidderivater, fremgangsmate for fremstilling derav, medikamenter inneholdende denne forbindelsen og anvendelse derav som et hypolipid | |
| NO20064456L (no) | Thiadiazolidinoner som GSK-3 inhibitorer | |
| NO20084845L (no) | 2-pyrazinonderivater for behandling av sykdom eller tilstander der inhibiering av neutrofil elastaseaktivitetet er gunstig | |
| TW200617001A (en) | Novel glucitol derivative, its prodrug, their salt and diabetic therapeutic agent containing the same | |
| DOP2001000243A (es) | Derivados de pirazol | |
| NO20082643L (no) | Isokinolinaminopyrazolderivater, deres fremstilling og anvendelse som farmasoytiske midler for behandling av kreft | |
| NO20072389L (no) | Substituerte benzokinolizinderivater | |
| MXPA04009784A (es) | Tiazolidin-4-carbonitrilos y analogos y su uso como inhibidores de dipeptidil-peptidas. | |
| BRPI0508243A (pt) | derivados de anéis fundidos nitrogenados, composições medicinais contendo os derivados e uso destas como drogas | |
| EP1637539A4 (en) | PYRAZOL DERIVATIVE MEDICAMENT COMPOSITION CONTAINING THEREOF AND INTERMEDIATE PRODUCT FOR THE PRODUCTION THEREOF | |
| NO20082112L (no) | 3-Amino-2-arylpropylazaindoler og deres anvendelse | |
| ATE442349T1 (de) | Diacylglycerol-acyltransferase-hemmer | |
| TW200635878A (en) | Hydroxybiphenylcarboxylic acids and derivatives, processes for preparing them and their use | |
| TW200631951A (en) | 1-Substituted-3-(β-D-glycopyranosyl)nitrogen-containing heterocyclic compound and a medical composition containing the same | |
| TW200616985A (en) | Salicylthiazoles substituted by diphenylamine or diphenylamine derivatives, process for their preparation and their use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |